Lead Product(s): NK cell therapy
Therapeutic Area: Oncology
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 21, 2020
Collaboration will leverage Onko-Innate’s deep expertise in NK Cell Tumor Biology to discover novel therapies in immuno-oncology and cell therapy.